First AD

Second AD

D. Ross Camidge, MD, PhD, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.  

Differences Between DNA and RNA Testing for NRG1

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers

OncLive News Network®

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.  

Prevalence of NRG1 Fusions in Lung Cancer

Standard Treatments for NRG1 Fusion+ NSCLC

Ongoing Research Efforts Targeting NRG1 in Lung Cancer

Efficacy With NRG1-Directed Agents in NSCLC

Prognosis, Rarity of NRG1+ Pancreatic Cancer

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers